Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3 -ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment

Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3 -ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment

Abstract only

Saved in:
Bibliographic Details
Published in:Journal of clinical oncology Vol. 36; no. 15_suppl; p. 7017
Main Authors: Levis, Mark J., Smith, Catherine Choy, Ishizuka, Koji, Kobayashi, Ken, Arunachalam, Meena, Wang, Yibin, Lazzaretto, Deborah, Cortes, Jorge E.
Format: Journal Article
Language:English
Published: 20-05-2018
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/JCO.2018.36.15_suppl.7017